GlassScriptPhysician profile
John Barry Carmody
NPI 1619187648
$5,186.96
in general payments reported to CMS, 2019-2025
33 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $265 · 2021: $696 · 2022: $774 · 2023: $876 · 2024: $867 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943 · Entertainment: $89.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.87 |
| Entertainment | $89.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $977.61 | 2019-2025 | Argos, Clareon, Centurion |
| Abbvie INC. | $494.78 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $400.21 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $349.32 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $285.19 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $239.64 | 2020-2023 | Cequa |
| Biotissue Holdings INC. | $220.54 | 2022-2025 | |
| Amgen INC. | $212.35 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $171.08 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $163.07 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $151.10 | 2021-2022 | |
| Harrow Eye, LLC | $150.76 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $142.92 | 2024-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $139.41 | 2021 | |
| Kala Pharmaceuticals, INC. | $135.40 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $134.28 | 2024 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2020 | |
| Horizon Therapeutics Plc | $107.79 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.52 | 2019-2021 | |
| Optos, INC. | $89.45 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $67.13 | 2019-2021 | |
| Dompe US, INC. | $66.93 | 2021-2025 | Oxervate |
| Coopervision INC. | $50.59 | 2022-2025 | Clariti Contact Lens |
| Thea Pharma INC. | $39.00 | 2022-2025 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $29.55 | 2023 | Acuvue |
| Shire North American Group INC | $23.88 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.80 | 2024 | Syfovre |
| Rxsight INC | $21.79 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Axogen | $18.36 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.88 | 2021 | |
| Omeros Corporation | $14.42 | 2020 | |
| Glaukos Corporation | $13.89 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carmody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.